European comparative clinical study of Inerpan: a new wound dressing in treatment of partial skin thickness burns.
Eleven European burns centres in five countries (Belgium, England, Germany, Italy, Switzerland) participated in a prospective, randomized clinical trial comparing a new wound dressing Inerpan with conventional dressings such as petroleum jelly gauze, petroleum jelly gauze with antibiotics and silver sulphadiazine cream. The indication was partial skin thickness burns and 62 patients were included. In each patient, two similar lesions (with respect to depth and surface area) were compared, one being treated with Inerpan, the other one with a control dressing. The following parameters were studied: healing time, quality of healing, intensity of pain, local tolerance and frequency of dressing changes. Analysis of the results showed that Inerpan-treated sites healed faster than conventional ones, and were associated with a highly significant reduction of pain. The frequency of dressing changes was greatly reduced and the local tolerance was good.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000596:Amino Acids / Q000627:therapeutic use; D002056:Burns / Q000473:pathology / Q000628:therapy*; D002648:Child; D005060:Europe; D005260:Female; D006801:Humans; D007930:Leucine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009779:Occlusive Dressings; D010577:Petrolatum / Q000008:administration & dosage; D011099:Polyglutamic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011446:Prospective Studies; D012837:Silver Sulfadiazine / Q000627:therapeutic use; D012867:Skin / Q000473:pathology
D000596:Amino Acids; C078325:inerpan; D011099:Polyglutamic Acid; D010577:Petrolatum; D007930:Leucine; D012837:Silver Sulfadiazine